2-Apr-2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 2-Apr 4:30 PM ET)
Globe Newswire (Tue, 17-Mar 4:30 PM ET)
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Globe Newswire (Mon, 16-Mar 7:00 AM ET)
Business Wire (Mon, 9-Mar 1:57 PM ET)
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Globe Newswire (Thu, 19-Feb 4:30 PM ET)
Olema Oncology to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Feb 4:30 PM ET)
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Globe Newswire (Fri, 30-Jan 4:01 PM ET)
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 5-Jan 7:00 AM ET)
Market Chameleon (Fri, 21-Nov 3:34 AM ET)
Market Chameleon (Thu, 20-Nov 5:33 AM ET)
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Olema Pharmaceuticals trades on the NASDAQ stock market under the symbol OLMA.
As of April 2, 2026, OLMA stock price declined to $15.06 with 863,522 million shares trading.
OLMA has a beta of 1.16, meaning it tends to be more sensitive to market movements. OLMA has a correlation of 0.02 to the broad based SPY ETF.
OLMA has a market cap of $1.31 billion. This is considered a Small Cap stock.
In the last 3 years, OLMA traded as high as $36.26 and as low as $2.86.
The top ETF exchange traded funds that OLMA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
OLMA has outperformed the market in the last year with a price return of +350.9% while the SPY ETF gained +18.2%. However, in the short term, OLMA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -39.8% vs -3.6% return in SPY. But in the last 2 weeks, OLMA shares have fared better than the market returning +3.4% compared to SPY -0.6%.
OLMA support price is $14.32 and resistance is $15.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OLMA shares will trade within this expected range on the day.